Home  |  Contact

Cellosaurus BT-474 (CVCL_0179)

Cell line name BT-474
Synonyms Bt-474; BT474
Accession CVCL_0179
Resource Identification Initiative To cite this cell line use: BT-474 (RRID:CVCL_0179)
Comments Part of: AKT genetic alteration cell panel (ATCC TCP-1029).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
Part of: ERK genetic alteration cell panel (ATCC TCP-1033).
Part of: GrayJW breast cancer cell line panel.
Part of: ICBP43 breast cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Population: Caucasian.
Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); 45.8 hours (PubMed=24389870); ~60-80 hours (CLS=300131); ~100 hours (DSMZ=ACC-64); 92.49 hours (GrayJW panel).
Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep phosphoproteome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Glycoproteome analysis by proteomics.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870).
Derived from site: In situ; Breast; UBERON=UBERON_0000310.
Sequence variations
  • Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (PubMed=26865974).
  • Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (PubMed=21247443; PubMed=26865974).
  • Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (PubMed=21247443; PubMed=26865974).
  • Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (PubMed=26865974).
  • Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (PubMed=21247443; PubMed=26865974).
  • Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (PubMed=26865974; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (PubMed=26865974; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (PubMed=26865974; ATCC; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (PubMed=19593635; PubMed=26865974; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=26865974; PubMed=28889351; ATCC; Cosmic-CLP; DepMap).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*29:02
HLA-BB*07:02
HLA-CC*07:02,16:01
Class II
HLA-DQDQB1*03:04,06:02
HLA-DRDRB1*15:01,15:01

Source: PubMed=26589293
Class I
HLA-AA*02:46,29:02
HLA-BB*07:02,35:08
HLA-CC*07:02,16:01
Class II
HLA-DQDQB1*03:02,06:02
HLA-DRDRB1*04:05,15:01

Source: CLS=300131
Class I
HLA-AA*01:01:01,05:02:01
HLA-BB*07:02:01,20:03:01
HLA-CC*07:02:01,16:01:01
Class II
HLA-DPDPB1*04:01:01G,05:01:01G
HLA-DQDQA1*01:02:01,03:03:01
DQB1*06:02:01
HLA-DRDRB1*04:01,15:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.6
Native American0
East Asian, North2.47
East Asian, South0
South Asian0
European, North70.19
European, South26.74
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_AQ07 (BT-474 Clone 5)CVCL_A4CL (BT-474 Ecadherin EmGFP)CVCL_AR96 (BT-474 EEI)
CVCL_AR86 (BT-474 Tam1)CVCL_A4AK (BT-474 Tam2)CVCL_C9CU (BT-474-Luc2)
CVCL_4Y08 (BT-474/CMV-Luc)CVCL_IP20 (BT-474c1)CVCL_YX79 (BT474 A3)
CVCL_4V65 (BT474-5FU[r])CVCL_ZL46 (BT474-J4)CVCL_EI02 (BT474-LAPRa)
CVCL_EI03 (BT474-LAPRb)CVCL_VL01 (BT474-LR)CVCL_A2GH (LR-BT474)
Sex of cell Female
Age at sampling 60Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; Genomics_Center_BCF_Technion; KCLB; PubMed=25877200; PubMed=28889351

Markers:
AmelogeninX
CSF1PO10,11
D2S133819
D3S135817
D5S81811,13
D7S8209,12
D8S117910,12
D13S31711
D16S5399,11
D18S5113,18
D19S43314,17
D21S1128,32.2
FGA22,25
Penta D9,14
Penta E5
TH017
TPOX8
vWA15,16

Run an STR similarity search on this cell line
Web pages http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=BT-474
https://lincs.hms.harvard.edu/resources/reagents/icbp43/
https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
https://tcpaportal.org/mclp/
Publications

PubMed=212572; DOI=10.1093/jnci/61.4.967
Lasfargues E.Y., Coutinho W.G., Redfield E.S.
Isolation of two human tumor epithelial cell lines from solid breast carcinomas.
J. Natl. Cancer Inst. 61:967-978(1978)

PubMed=94035; DOI=10.1007/BF02618252
Lasfargues E.Y., Coutinho W.G., Dion A.S.
A human breast tumor cell line (BT-474) that supports mouse mammary tumonr virus replication.
In Vitro 15:723-729(1979)

DOI=10.1007/978-1-4757-0019-0_7
Lasfargues E.Y., Coutinho W.G.
Human breast tumor cells in culture; new concepts in mammary carcinogenesis.
(In) New frontiers in mammary pathology; Hollmann K.H., de Brux J., Verley J.M. (eds.); pp.117-143; Plenum Press; New York (1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=1961733; DOI=10.1073/pnas.88.23.10657
Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.
Mutations in p53 as potential molecular markers for human breast cancer.
Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991)

DOI=10.1016/B978-0-12-333530-2.50009-5
Leibovitz A.
Cell lines from human breast.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994)

PubMed=7842014; DOI=10.1038/ng1094-155
Guan X.-Y., Meltzer P.S., Dalton W.S., Trent J.M.
Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection.
Nat. Genet. 8:155-161(1994)

PubMed=9671407; DOI=10.1038/sj.onc.1201814
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Oncogene 16:2865-2878(1998)

PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B
Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J., Larsson C.
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Genes Chromosomes Cancer 28:308-317(2000)

PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)

PubMed=11687795; DOI=10.1038/ng754
Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.
Assembly of microarrays for genome-wide measurement of DNA copy number.
Nat. Genet. 29:263-264(2001)

PubMed=12353263; DOI=10.1002/gcc.10107
Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Genes Chromosomes Cancer 35:204-218(2002)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=16142302; DOI=10.3892/ijo.27.4.881
de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.
Molecular characterization of breast cancer cell lines by a low-density microarray.
Int. J. Oncol. 27:881-892(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16195238; DOI=10.1093/carcin/bgi231
Hussain-Hakimjee E.A., Peng X.-J., Mehta R.R., Mehta R.G.
Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5.
Carcinogenesis 27:551-559(2006)

PubMed=16417655; DOI=10.1186/bcr1370
Shadeo A., Lam W.L.
Comprehensive copy number profiles of breast cancer cell model genomes.
Breast Cancer Res. 8:R9.1-R9.14(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=17334996; DOI=10.1002/gcc.20438
Jonsson G., Staaf J., Olsson E., Heidenblad M., Vallon-Christersson J., Osoegawa K., de Jong P.J., Oredsson S.M., Ringner M., Hoglund M., Borg A.
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
Genes Chromosomes Cancer 46:543-558(2007)

PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004
Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J.
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
Mol. Oncol. 1:84-96(2007)

PubMed=18386134; DOI=10.1007/s10585-008-9169-z
Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.
Clin. Exp. Metastasis 25:549-557(2008)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

PubMed=19671800; DOI=10.1158/0008-5472.CAN-08-4490
Liu L., Greger J.G., Shi H., Liu Y., Greshock J., Annan R., Halsey W., Sathe G.M., Martin A.-M., Gilmer T.M.
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Cancer Res. 69:6871-6878(2009)

PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S.P., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009)

CLPUB00423
Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010), Griffith University, Australia

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=20070913; DOI=10.1186/1471-2407-10-15
Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
BMC Cancer 10:15.1-15.10(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21247443; DOI=10.1186/gb-2011-12-1-r6
Edgren H., Murumagi A., Kangaspeska S., Nicorici D., Hongisto V., Kleivi K., Rye I.H., Nyberg S., Wolf M., Borresen-Dale A.-L., Kallioniemi O.-P.
Identification of fusion genes in breast cancer by paired-end RNA-sequencing.
Genome Biol. 12:R6.1-R6.13(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=23151021; DOI=10.1186/1471-2164-13-619
Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619.1-619.14(2012)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=24389870; DOI=10.1038/srep03576
Strauch M., Ludke A., Munch D., Laudes T., Galizia C.G., Martinelli E., Lavra L., Paolesse R., Ulivieri A., Catini A., Capuano R., Di Natale C.
More than apples and oranges -- detecting cancer with a fruit fly's antenna.
Sci. Rep. 4:3576-3576(2014)

PubMed=24456987; DOI=10.1186/1755-8166-7-8
Rondon-Lagos M., Verdun Di Cantogno L., Marchio C., Rangel N., Payan-Gomez C., Gugliotta P., Botta C., Bussolati G., Ramirez-Clavijo S.R., Pasini B., Sapino A.
Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis.
Mol. Cytogenet. 7:8.1-8.14(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050
Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., Lee S.-I., Blau C.A., Villen J.
The proteomic landscape of triple-negative breast cancer.
Cell Rep. 11:630-644(2015)

PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021
Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E., Kammerer B.
Metabolic profiling of breast cancer: differences in central metabolism between subtypes of breast cancer cell lines.
J. Chromatogr. B 1000:95-104(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26865974; DOI=10.1186/s13742-016-0113-x
Ciotlos S., Mao Q., Zhang R.Y., Li Z.-Y., Chin R., Gulbahce N., Liu S.J., Drmanac R., Peters B.A.
Whole genome sequence analysis of BT-474 using Complete Genomics' standard and long fragment read technologies.
GigaScience 5:8.1-8.17(2016)

PubMed=27362937; DOI=10.1371/journal.pone.0157290
Carrier M., Joint M., Lutzing R., Page A., Rochette-Egly C.
Phosphoproteome and transcriptome of RA-responsive and RA-resistant breast cancer cell lines.
PLoS ONE 11:E0157290-E0157290(2016)

PubMed=27378269; DOI=10.1186/s12885-016-2452-5
Kangaspeska S., Hultsch S., Jaiswal A., Edgren H., Mpindi J.P., Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
BMC Cancer 16:378.1-378.17(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
J. Proteome Res. 16:1391-1400(2017)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=32942617; DOI=10.3390/cancers12092630
Lee H.J., Shin S., Kang J., Han K.-C., Kim Y.H., Bae J.-W., Park K.H.
HSP90 inhibitor, 17-DMAG, alone and in combination with lapatinib attenuates acquired lapatinib-resistance in ER-positive, HER2-overexpressing breast cancer cell line.
Cancers (Basel) 12:2630.1-2630.16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0006012/4902
ATCC; CRL-7913 - Discontinued
ATCC; HTB-20
BCRC; 60359
BCRJ; 0353
CLS; 300131
DSMZ; ACC-64
IBRC; C10140
ICLC; HTL00008
KCB; KCB 2011115YJ
KCLB; 60062
NCBI_Iran; C435
Cell line databases/resources CLO; CLO_0002042
MCCL; MCC:0000070
CLDB; cl497
CLDB; cl498
CLDB; cl4997
cancercelllines; CVCL_0179
CCRID; 1101HUM-PUMC000129
CCRID; 1102HUM-NIFDC00023
CCRID; 3101HUMTCHu143
CCRID; 4201HUM-CCTCC00636
Cell_Model_Passport; SIDM00963
Cosmic-CLP; 946359
DepMap; ACH-000927
DSMZCellDive; ACC-64
IGRhCellID; BT474
LINCS_HMS; 50106
LINCS_LDP; LCL-1308
TOKU-E; 694
Anatomy/cell type resources BTO; BTO:0001932
Biological sample resources BioSample; SAMN01821539
BioSample; SAMN01821618
BioSample; SAMN03473029
BioSample; SAMN10988308
BioSamples; SAMEA3516847
BioSamples; SAMEA3516848
BioSamples; SAMEA3516849
Chemistry resources ChEMBL-Cells; CHEMBL3307636
ChEMBL-Targets; CHEMBL614529
GDSC; 946359
PharmacoDB; BT474_109_2019
PubChem_Cell_line; CVCL_0179
Encyclopedic resources Wikidata; Q54798460
Experimental variables resources EFO; EFO_0001093
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-TABM-157
ArrayExpress; E-TABM-244
GEO; GSM1716
GEO; GSM1725
GEO; GSM69198
GEO; GSM73557
GEO; GSM73702
GEO; GSM115110
GEO; GSM147888
GEO; GSM147957
GEO; GSM149981
GEO; GSM149989
GEO; GSM149997
GEO; GSM155210
GEO; GSM184392
GEO; GSM184393
GEO; GSM213707
GEO; GSM213717
GEO; GSM213718
GEO; GSM213719
GEO; GSM213737
GEO; GSM213740
GEO; GSM213743
GEO; GSM213745
GEO; GSM217615
GEO; GSM274657
GEO; GSM276780
GEO; GSM320173
GEO; GSM344341
GEO; GSM344391
GEO; GSM350504
GEO; GSM388211
GEO; GSM421861
GEO; GSM533397
GEO; GSM533412
GEO; GSM590105
GEO; GSM679677
GEO; GSM679678
GEO; GSM679679
GEO; GSM679680
GEO; GSM679681
GEO; GSM679682
GEO; GSM679683
GEO; GSM679684
GEO; GSM679685
GEO; GSM679686
GEO; GSM679687
GEO; GSM679688
GEO; GSM679689
GEO; GSM679690
GEO; GSM679691
GEO; GSM783958
GEO; GSM799168
GEO; GSM799169
GEO; GSM799170
GEO; GSM799171
GEO; GSM799172
GEO; GSM799173
GEO; GSM847198
GEO; GSM847453
GEO; GSM843476
GEO; GSM886892
GEO; GSM887957
GEO; GSM903063
GEO; GSM903064
GEO; GSM903065
GEO; GSM903066
GEO; GSM903067
GEO; GSM903068
GEO; GSM903069
GEO; GSM967821
GEO; GSM1008891
GEO; GSM1053692
GEO; GSM1172941
GEO; GSM1172853
GEO; GSM1214587
GEO; GSM1238128
GEO; GSM1264068
GEO; GSM1264073
GEO; GSM1264110
GEO; GSM1264115
GEO; GSM1374408
GEO; GSM1374409
GEO; GSM1374410
GEO; GSM1401649
GEO; GSM1669630
GEO; GSM2176271
GEO; GSM2176272
Polymorphism and mutation databases Cosmic; 687464
Cosmic; 871138
Cosmic; 904351
Cosmic; 923058
Cosmic; 934520
Cosmic; 946359
Cosmic; 970088
Cosmic; 979721
Cosmic; 1000122
Cosmic; 1017168
Cosmic; 1018460
Cosmic; 1046934
Cosmic; 1047699
Cosmic; 1071903
Cosmic; 1129654
Cosmic; 1136353
Cosmic; 1176605
Cosmic; 1287890
Cosmic; 1289383
Cosmic; 1308996
Cosmic; 1434947
Cosmic; 1523771
Cosmic; 1603191
Cosmic; 1609475
Cosmic; 1945863
Cosmic; 2165003
Cosmic; 2301523
Cosmic; 2318376
Cosmic; 2361356
IARC_TP53; 4
LiGeA; CCLE_516
Progenetix; CVCL_0179
Proteomic databases PRIDE; PXD002281
PRIDE; PXD002635
PRIDE; PXD004357
PRIDE; PXD005390
PRIDE; PXD008222
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number44